LLYEli Lilly and CompanySigning up patients
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 700 (planned)
- Started
- Mar 27, 2025
- Main results expected
- May 2029
- Fully finished
- Feb 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Disease-Free Survival (DFS) by Investigator Assessment
Measured over: Randomization to disease recurrence or death from any cause (Estimated as approximately 4 years).
Part B: Progression-Free Survival (PFS) by BICR
Measured over: Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06890598 · record last updated 2026-11-04 · checked 2026-11-09 15:42 UTC